cyclosporine + prednisolone acetate (Fovea Pharmaceuticals)

Prednisporin (FOV1101) is a topical ophthalmic fixed-dose combination therapy consisting of low-dose prednisolone acetate and cyclosporine A. Developed by Fovea Pharmaceuticals (later acquired by Sanofi), it is designed to treat persistent allergic conjunctivitis and chronic inflammatory conjunctivitis. Prednisolone acetate is a corticosteroid that acts as a glucocorticoid receptor agonist to suppress inflammation, while cyclosporine A is an immunosuppressant that inhibits calcineurin-mediated T-cell activation. The combination is formulated to maintain the anti-inflammatory efficacy of potent steroids while providing an improved safety profile, specifically aiming to avoid the increase in intra-ocular pressure typically associated with high-dose corticosteroid use. The drug was originally discovered by CombinatoRx using its proprietary combination discovery platform and licensed to Fovea for ophthalmic indications.

Brand names

Prednisporin

Other names

cyclosporine and prednisolone acetate